For individuals on GLP-1 agonists who may feel less energetic during dose escalation periods, walking is the easiest and most sustainable activity
Always check this date before use
In clinical trials studying semaglutide 2.4 mg (Wegovy dosing), body composition data shows that approximately 25-40% of total weight loss came from lean mass in participants who were not engaged in structured exercise programs
But how do they operate, and what makes them so different
You received your full dose of semaglutide regardless of which tissue layer it entered
As a GLP-1 receptor agonist, semaglutide suppresses appetite, delays stomach emptying, and stimulates insulin secretion.[1] While semaglutide was originally developed for patients with T2D as a glucose-lowering medication, clinical trials later demonstrated significant weight loss in patients taking semaglutide.[6] Additional studies also support semaglutides effectiveness in promoting weight loss for non-diabetics.[1,7,8] Wegovy is the only semaglutide medication approved by the U.S
